MITF and neoplasm: Moreover, this can create a situation of enhanced tolerance during BRAF and MEK inhibitor therapy, because the number of tumour‐associated macrophages increases in response to the inhibitors, and this correlates with increased expression of MITF during treatment (Smith et al., 2014).